Proposed Data Collections Submitted for Public Comment and Recommendations, 69663-69664 [E8-27448]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 224 / Wednesday, November 19, 2008 / Notices
FEDERAL MARITIME COMMISSION
FEDERAL RESERVE SYSTEM
Notice of Change to Meeting
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
Agency Holding the Meeting:
Federal Maritime Commission.
Federal Register Citation of Previous
Announcement: 73 FR 67869.
Previously Announced Time and Date
of the Meeting: 10 a.m. on November 20,
2008.
Change:
1. The addition of Item 2 to the Open
Session of the Meeting: Item 2—FY 2009
Budget Status Report.
For More Information Contact:
Karen V. Gregory, Secretary, (202)
523–5725.
Karen V. Gregory,
Secretary.
[FR Doc. E8–27598 Filed 11–17–08; 4:15 pm]
BILLING CODE 6730–01–P
FEDERAL MARITIME COMMISSION
Ocean Transportation Intermediary
License; Applicants
Notice is hereby given that the
following applicants have filed with the
Federal Maritime Commission an
application for license as a Non-Vessel
Operating Common Carrier and Ocean
Freight Forwarder—Ocean
Transportation Intermediary pursuant to
section 19 of the Shipping Act of 1984
as amended (46 U.S.C. Chapter 409 and
46 CFR 515).
Persons knowing of any reason why
the following applicants should not
receive a license are requested to
contact the Office of Transportation
Intermediaries, Federal Maritime
Commission, Washington, DC 20573.
cprice-sewell on PROD1PC64 with NOTICES
Non-Vessel Operating Common Carrier
and Ocean Freight Forwarder
Transportation Intermediary
Applicants
InterChez Global Services, Inc., 3924
Clock Pointe Trail, Suite 101, Stow,
OH 44224; Officer: Melissa F. Lines,
Vice President, (Qualifying
Individual).
Morrison Express Corporation (USA),
2000 Hughes Way, El Segundo, CA
90248; Officer: Douglas E. Haring,
Vice President, (Qualifying
Individual).
Dated: November 14, 2008.
Karen V. Gregory,
Secretary.
[FR Doc. E8–27499 Filed 11–18–08; 8:45 am]
BILLING CODE 6730–01–P
VerDate Aug<31>2005
15:14 Nov 18, 2008
Jkt 217001
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than December 12,
2008.
A. Federal Reserve Bank of Atlanta
(Steve Foley, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30309:
1. Protective Life Corporation,
Birmingham, Alabama; to become a
bank holding company by acquiring 100
percent of the voting shares of Bonifay
Holding Company, Inc., and its
subsidiary, The Bank of Bonifay, both of
Bonifay, Florida.
B. Federal Reserve Bank of Kansas
City (Todd Offerbacker, Assistant Vice
President) 925 Grand Avenue, Kansas
City, Missouri 64198-0001:
1. Union State Banc Holding
Company, Clay Center, Kansas; to
become a bank holding company by
acquiring 100 percent of the voting
shares of Union State Bank, Clay Center,
Kansas.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
69663
C. Federal Reserve Bank of San
Francisco (Tracy Basinger, Director,
Regional and Community Bank Group)
101 Market Street, San Francisco,
California 94105-1579:
1. Marlin Business Services
Corporation., Mount Laurel, New Jersey;
to become a bank holding company by
acquiring 100 percent of the voting
shares of Marlin Business Bank, Salt
Lake City, Utah.
In connection with this application,
Applicant also has applied to engage
indirectly in leasing activities through
Marlin Leasing Corporation, Mount
Laurel, New Jersey, pursuant to
225.28(b)(3) of Regulation Y.
Board of Governors of the Federal Reserve
System, November 14, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–27470 Filed 11–18–08; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–09–09AF]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 or send
comments to Maryam Daneshvar PhD,
CDC Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
E:\FR\FM\19NON1.SGM
19NON1
69664
Federal Register / Vol. 73, No. 224 / Wednesday, November 19, 2008 / Notices
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
‘‘Evaluation of Pharmacy Syringe
Access Linked to HIV Testing for
Injection Drug Users in New York City
(Pharm-HIV)’’—New—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP). Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
HIV continues to be one of the leading
causes of illness and death in the US,
especially among black and Hispanic
communities. For injection drug users
(IDU), who are at high risk of acquiring
HIV infection, HIV testing may not be
readily accessible. In 2001, the New
York State Legislature established an
Expanded Syringe Access
Demonstration Program (ESAP) in New
York City which made syringes
available through participating
City; ten of which will test a model that
refers injection-drug-using syringe
customers for HIV testing to local HIV
testing sites. Two ESAP pharmacies will
evaluate the feasibility of offering and
performing HIV counseling and testing
in the pharmacy for injection-drug-using
syringe customers.
Two types of respondents will
provide the individual-level data; fortyeight adult (age ≥18 yrs) pharmacy staff
members will be surveyed to learn about
pharmacy staff attitudes and behaviors
regarding HIV testing and referral. The
other respondent group will be 442
adult (age ≥18 yrs) injection-drug-using
syringe customers who will complete a
brief quantitative interview after HIV
referral or HIV testing is offered to them.
HIV-seropositive injection-drug-using
syringe customers identified during HIV
testing will be immediately linked to
social and medical services. There is no
cost to respondents other than their
time.
pharmacies for injection drug users.
ESAP thus helped to reduce the burden
of HIV by increasing access to sterile
syringe sources. The ESAP allows for
regular contact between pharmacists
and their injection-drug-using syringe
customers, thus paving the way for
pharmacies to act as access points to
health and social services among IDU
customers. The expansion of pharmacy
services to include referrals for
injection-drug-using syringe customers
is based on the successes of ESAP,
which provides many services beyond
syringe exchange.
This project involves two kinds of
studies: testing service models at
pharmacies and, interviewing
individuals regarding the availability of
syringes through pharmacies. For testing
service models CDC will collaborate
with the New York Academy of
Medicine (NYAM) to implement this
project for a period of three years.
The NYAM will identify 12 ESAP
pharmacies in East Harlem, New York
ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents
Types of data collection
Pharmacy telephone screening and enrollment form ......................................
Pharmacy staff surveys—baseline, every six months x 3, and at end of
study. ............................................................................................................
Pharmacy staff brief surveys—monthly except when 6 monthly surveys are
completed. ....................................................................................................
Pharmacy daily syringe sales log ....................................................................
Injection-drug-using syringe customer surveys ...............................................
Total ..........................................................................................................
Dated: November 7, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–27448 Filed 11–18–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
cprice-sewell on PROD1PC64 with NOTICES
Centers for Disease Control and
Prevention
Subcommittee for Dose
Reconstruction Reviews (SDRR),
Advisory Board on Radiation and
Worker Health (ABRWH), National
Institute for Occupational Safety and
Health (NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
VerDate Aug<31>2005
15:14 Nov 18, 2008
Jkt 217001
1
10/60
4
48
5
20/60
80
12
12
442
19
600
1
10/60
5/60
30/60
38
600
221
........................
........................
........................
943
Time and Date: 9:30 a.m.–5 p.m.,
December 8, 2008.
Place: Cincinnati Airport Marriott, 2395
Progress Drive, Hebron, Kentucky 41018.
Telephone (859) 334–4611, Fax (859) 334–
4619.
Status: Open to the public, but without a
public comment period. To access by
conference call dial the following
information 1(866) 659–0537, Participant
Pass Code 9933701.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation Program
Act of 2000 to advise the President on a
variety of policy and technical functions
required to implement and effectively
manage the new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that have
been promulgated by the Department of
Health and Human Services (HHS) as a final
rule; advice on methods of dose
reconstruction which have also been
promulgated by HHS as a final rule; advice
Frm 00066
Fmt 4703
Total burden
(in hours)
24
announces the following meeting for the
aforementioned subcommittee:
PO 00000
Average
burden per
response
(in hours)
Number of
responses per
respondent
Sfmt 4703
on the scientific validity and quality of dose
estimation and reconstruction efforts being
performed for purposes of the compensation
program; and advice on petitions to add
classes of workers to the Special Exposure
Cohort (SEC).
In December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS, which
subsequently delegated this authority to CDC.
NIOSH implements this responsibility for
CDC. The charter was issued on August 3,
2001, renewed at appropriate intervals, and
will expire on August 3, 2009.
Purpose: The Advisory Board is charged
with (a) Providing advice to the Secretary,
HHS, on the development of guidelines
under Executive Order 13179; (b) providing
advice to the Secretary, HHS, on the
scientific validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary on
whether there is a class of employees at any
Department of Energy facility who were
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is reasonable likelihood
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 73, Number 224 (Wednesday, November 19, 2008)]
[Notices]
[Pages 69663-69664]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-27448]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-09-09AF]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960 or
send comments to Maryam Daneshvar PhD, CDC Reports Clearance Officer,
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information
[[Page 69664]]
technology. Written comments should be received within 60 days of this
notice.
Proposed Project
``Evaluation of Pharmacy Syringe Access Linked to HIV Testing for
Injection Drug Users in New York City (Pharm-HIV)''--New--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
HIV continues to be one of the leading causes of illness and death
in the US, especially among black and Hispanic communities. For
injection drug users (IDU), who are at high risk of acquiring HIV
infection, HIV testing may not be readily accessible. In 2001, the New
York State Legislature established an Expanded Syringe Access
Demonstration Program (ESAP) in New York City which made syringes
available through participating pharmacies for injection drug users.
ESAP thus helped to reduce the burden of HIV by increasing access to
sterile syringe sources. The ESAP allows for regular contact between
pharmacists and their injection-drug-using syringe customers, thus
paving the way for pharmacies to act as access points to health and
social services among IDU customers. The expansion of pharmacy services
to include referrals for injection-drug-using syringe customers is
based on the successes of ESAP, which provides many services beyond
syringe exchange.
This project involves two kinds of studies: testing service models
at pharmacies and, interviewing individuals regarding the availability
of syringes through pharmacies. For testing service models CDC will
collaborate with the New York Academy of Medicine (NYAM) to implement
this project for a period of three years.
The NYAM will identify 12 ESAP pharmacies in East Harlem, New York
City; ten of which will test a model that refers injection-drug-using
syringe customers for HIV testing to local HIV testing sites. Two ESAP
pharmacies will evaluate the feasibility of offering and performing HIV
counseling and testing in the pharmacy for injection-drug-using syringe
customers.
Two types of respondents will provide the individual-level data;
forty-eight adult (age >=18 yrs) pharmacy staff members will be
surveyed to learn about pharmacy staff attitudes and behaviors
regarding HIV testing and referral. The other respondent group will be
442 adult (age >=18 yrs) injection-drug-using syringe customers who
will complete a brief quantitative interview after HIV referral or HIV
testing is offered to them. HIV-seropositive injection-drug-using
syringe customers identified during HIV testing will be immediately
linked to social and medical services. There is no cost to respondents
other than their time.
Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Types of data collection respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Pharmacy telephone screening and enrollment form 24 1 10/60 4
Pharmacy staff surveys--baseline, every six 48 5 20/60 80
months x 3, and at end of study................
Pharmacy staff brief surveys--monthly except 12 19 10/60 38
when 6 monthly surveys are completed...........
Pharmacy daily syringe sales log................ 12 600 5/60 600
Injection-drug-using syringe customer surveys... 442 1 30/60 221
---------------------------------------------------------------
Total....................................... .............. .............. .............. 943
----------------------------------------------------------------------------------------------------------------
Dated: November 7, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E8-27448 Filed 11-18-08; 8:45 am]
BILLING CODE 4163-18-P
